

# Max J Gordon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9067578/publications.pdf>

Version: 2024-02-01

39  
papers

621  
citations

623734

14  
h-index

610901

24  
g-index

39  
all docs

39  
docs citations

39  
times ranked

907  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. <i>Cancer</i> , 2018, 124, 3192-3200.	4.1	70
2	Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival. <i>European Journal of Haematology</i> , 2016, 97, 445-452.	2.2	55
3	Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 734-736.	2.5	42
4	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	4.1	40
5	Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1520-1532.	4.1	39
6	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. <i>PLoS ONE</i> , 2015, 10, e0143685.	2.5	32
7	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 46-52.	1.2	28
8	SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 1890-1900.	3.5	27
9	Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 461-465.	1.3	23
10	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	7.0	23
11	CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. <i>Leukemia Research</i> , 2017, 53, 39-49.	0.8	22
12	Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 501-503.	2.5	22
13	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
14	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
15	Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. <i>British Journal of Haematology</i> , 2021, 192, 720-728.	2.5	17
16	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2862-2870.	1.3	13
17	The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	2.5	13
18	Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 749-754.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 302-309.	2.3	11
20	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	4.1	11
21	The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. <i>Blood Advances</i> , 2022, 6, 2701-2706.	5.2	11
22	Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 2946-2950.	1.3	10
23	Refractory Autoimmune Cytopenias Treated With Venetoclax. <i>HemaSphere</i> , 2019, 3, e202.	2.7	10
24	Targeting neddylation effectively antagonizes nuclear factor- $\kappa$ B in chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 1566-1569.	1.3	8
25	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017, 10, 707-718.	2.2	8
26	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.8	5
27	A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. <i>British Journal of Haematology</i> , 2017, 178, 820-823.	2.5	4
28	Lymphoma of the Hands in a Patient With Rheumatoid Arthritis: Case Report. <i>Journal of Hand Surgery</i> , 2014, 39, 728-731.	1.6	3
29	MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 272-275.	2.5	3
30	Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia – response to Rider. <i>British Journal of Haematology</i> , 2016, 173, 327-328.	2.5	3
31	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	2.2	3
32	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3
33	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	1.4	3
34	An Unusual Case of Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e463-e464.	0.6	1
35	Effect of concurrent CYP3A4 interacting medications on ibrutinib outcomes in patients with CLL. <i>Journal of Clinical Oncology</i> , 2018, 36, e19514-e19514.	1.6	1
36	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. Leukemia and Lymphoma, 2021, , 1-11.	1.3	1
38	Unusual complications in the management of <scp>chronic lymphocytic leukemia</scp>. American Journal of Hematology, 2022, , .	4.1	1
39	Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma. Leukemia and Lymphoma, 2022, 63, 2041-2051.	1.3	1